SCHEMBL22729609

SCHEMBL22729609

Cc1cn(C)c(=O)c2c(C(=O)N3CC4CC4(c4cccc(Cl)c4Cl)C3)cn(C)c12

nearest known ligand 0.34

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.34
▸ HPGD P15428 3/20 0.34
▸ MAPT P10636 2/20 0.34
▸ NPSR1 Q6W5P4 2/20 0.34
▸ TSHR P16473 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ P2RX7 Q99572 7/20 0.33
▸ MGLL Q99685 6/20 0.33
▸ HSD17B10 Q99714 3/20 0.33
▸ LMNA P02545 1/20 0.33
▸ ALOX15 P16050 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ KDM4E B2RXH2 2/20 0.32
▸ GAA P10253 1/20 0.31
▸ CNR1 P21554 1/20 0.30
▸ CNR2 P34972 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29839278 1.00 ALDH1A1 (0.34) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL23116378 0.93 ALDH1A1 (0.36) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL22729560 0.88 MGLL (0.41) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL29839301 0.88 MGLL (0.41) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL22755326 0.87 MGLL (0.34) P2RX7MGLL
SCHEMBL22729457 0.86 TSHR (0.39) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL29839371 0.86 TSHR (0.39) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL22729600 0.86 ALDH1A1 (0.39) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL29839324 0.86 ALDH1A1 (0.39) ALDH1A1HPGDMAPTNPSR1TSHR
SCHEMBL23116386 0.85 ALDH1A1 (0.34) ALDH1A1HPGDMAPTNPSR1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — US disclosed
US-20210087186-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2021-03-25 — — US disclosed
EP-3747885-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2020-12-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210087186-A1 HETEROCYCLIC COMPOUND GBA1, GBA2, GALC ALDH1A1 2626/4885HPGD 1589/4885MAPT 356/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback